NUVALENT, INC.

$12.04 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest

Subscribe

About NUVALENT, INC.

Nuvalent, Inc. is a preclinical stage biopharmaceutical company focused on creating precisely targeted therapies for patients with cancer. The Company is advancing a pipeline of product candidates with parallel programs in cancers driven by genomic alterations in the ROS1 and ALK kinases, along with multiple discovery-stage research programs. The Company's pipeline includes NVL-520 and NVL-655. NVL-520, is a brain-penetrant ROS1-selective inhibitor, designed to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and also remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors. NVL-655, is a brain-penetrant ALK-selective inhibitor, designed to inhibit ALK fusions that express the normal ALK kinase domain without any drug-resistant mutations and also remain active in the presence of mutations conferring resistance to first, second, and third-generation ALK inhibitors.

Stock Analysis

last close $11.79
1-mo return -48.4%
3-mo return -43.5%
avg daily vol. 108.95T
52-week high 40.82
52-week low 11.69
market cap. $544M
forward pe -
annual div. -
roe -
ltg forecast -
dividend yield -
annual rev. $--
inst own. 99.4%
baraka

Subscribe now for daily local and international financial news

Subscribe